Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin B9Vitamin B9 (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia

Wiltshire et al., Medical Hypotheses, doi:10.1016/j.mehy.2020.110142
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hypothesis that high-dose folic acid (5-10mg daily) may be beneficial for COVID-19 related pulmonary hypertension and hypoxemia, based on systemic vascular effects showing improved endothelial function and prevention of nitrate tolerance with high-dose folic acid. Authors propose testing as an adjunct therapy for severe COVID-19 pneumonia patients being considered for inhaled nitric oxide, expecting potential improvements in oxygenation and prevention of tachyphylaxis.
Wiltshire et al., 26 Jul 2020, peer-reviewed, 5 authors. Contact: esko.wiltshire@otago.ac.nz.
This PaperVitamin B9All
High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia
Esko Wiltshire, Alexia Sophie Peña, Karen Mackenzie, Geoffrey Shaw, Jennifer Couper
Medical Hypotheses, doi:10.1016/j.mehy.2020.110142
Background: Pulmonary hypertension is a significant complication for some patients with COVID-19 pneumonia, especially those requiring intensive care. Tachyphylaxis to the current therapy, inhaled nitric oxide (iNO), is also common. In vitro, folic acid directly increases nitric oxide (NO) production and extends its duration of action; effects which could be of benefit in reversing pulmonary hypertension and severe hypoxaemia. Our work has shown that, in the systemic circulation, folic acid in high dose rapidly improves nitric oxide mediated vasodilation, by activating endothelial nitric oxide synthase (eNOS). Hypothesis: A similar effect of high dose folic acid on pulmonary endothelial function would be expected from the same mechanism and would lead to improvement in pulmonary perfusion. We therefore hypothesise that folic acid, 5 mg or greater, is a useful therapeutic option for pulmonary hypertension and/or refractory severe hypoxaemia, in patients with severe COVID-19 associated pneumonia in whom NO therapy is considered, with a very low risk of adverse effects.
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Appendix A. Supplementary data Supplementary data to this article can be found online at https:// doi.org/10.1016/j.mehy.2020.110142.
References
Arroliga, Sandur, Jacobsen, Tewari, Mustafa et al., Association between hyperhomocysteinemia and primary pulmonary hypertension, Respir Med
Chalupsky, Kračun, Kanchev, Bertram, Görlach, Folic acid promotes recycling of tetrahydrobiopterin and protects against hypoxia-induced pulmonary hypertension by recoupling endothelial nitric oxide synthase, Antioxid Redox Signal
Chen, Liu, Gao, Sun, Chao et al., Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in beijing, Clin Infect Dis
Doshi, Mcdowell, Moat, Payne, Durrant et al., Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering, Circulation
Dunlap, Weyer, None, Am Fam Phys
Gori, Burstein, Ahmed, Miner, Al-Hesayen et al., Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance, Circulation
Gündüz, Ekici, Özaydın, Ceylaner, Perez, Reversible pulmonary arterial hypertension in cobalamin-dependent cobalamin C disease due to a novel mutation in the MMACHC gene, Eur J Pediatr
Iodice, Chiara, Boenzi, Aiello, Monti et al., Cobalamin C defect presenting with isolated pulmonary hypertension, Pediatrics
Itelman, Wasserstrum, Segev, Avaky, Negru et al., Clinical characterization of 162 COVID-19 patients in Israel: preliminary report from a large tertiary center, Israel Med Assoc J
Joannides, Haefeli, Linder, Richard, Bakkali et al., Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo, Circulation
Mackenzie, Wiltshire, Gent, Hirte, Piotto et al., Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus, Pediatrics
Rosenzweig, Abman, Adatia, Beghetti, Bonnet et al., Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management, Eur Respir J
Stanhewicz, Kenney, Role of folic acid in nitric oxide bioavailability and vascular endothelial function, Nutr Rev
Stroes, Van Faassen, Yo, Martasek, Boer et al., Folic acid reverts dysfunction of endothelial nitric oxide synthase, Circ Res
Verhaar, Wever, Kastelein, Van Damm, Koomans et al., 5methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia, Circulation
Wiltshire, Peña, Mackenzie, Bose-Sundernathan, Gent et al., A NOS3 polymorphism determines endothelial response to folate in children with type 1 diabetes or obesity, J Pediatr
{ 'indexed': {'date-parts': [[2024, 1, 26]], 'date-time': '2024-01-26T17:46:38Z', 'timestamp': 1706291198036}, 'reference-count': 16, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2020, 10, 1]], 'date-time': '2020-10-01T00:00:00Z', 'timestamp': 1601510400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'funder': [ { 'DOI': '10.13039/501100000925', 'name': 'National Health and Medical Research Council', 'doi-asserted-by': 'publisher', 'award': ['519245']}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 10]]}, 'DOI': '10.1016/j.mehy.2020.110142', 'type': 'journal-article', 'created': {'date-parts': [[2020, 7, 26]], 'date-time': '2020-07-26T14:27:46Z', 'timestamp': 1595773666000}, 'page': '110142', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 14, 'title': 'High dose folic acid is a potential treatment for pulmonary hypertension, including when ' 'associated with COVID-19 pneumonia', 'prefix': '10.1016', 'volume': '143', 'author': [ {'given': 'Esko', 'family': 'Wiltshire', 'sequence': 'first', 'affiliation': []}, {'given': 'Alexia Sophie', 'family': 'Peña', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karen', 'family': 'MacKenzie', 'sequence': 'additional', 'affiliation': []}, {'given': 'Geoffrey', 'family': 'Shaw', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jennifer', 'family': 'Couper', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.mehy.2020.110142_b0005', 'first-page': '464', 'volume': '94', 'author': 'Dunlap', 'year': '2016', 'journal-title': 'Am Fam Phys'}, { 'issue': '1', 'key': '10.1016/j.mehy.2020.110142_b0010', 'doi-asserted-by': 'crossref', 'first-page': '1801916', 'DOI': '10.1183/13993003.01916-2018', 'article-title': 'Paediatric pulmonary arterial hypertension: updates on definition, ' 'classification, diagnostics and management', 'volume': '53', 'author': 'Rosenzweig', 'year': '2019', 'journal-title': 'Eur Respir J'}, { 'issue': '10', 'key': '10.1016/j.mehy.2020.110142_b0015', 'doi-asserted-by': 'crossref', 'first-page': '1531', 'DOI': '10.1086/425357', 'article-title': 'Inhalation of nitric oxide in the treatment of severe acute respiratory ' 'syndrome: a rescue trial in beijing', 'volume': '39', 'author': 'Chen', 'year': '2004', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.mehy.2020.110142_b0020', 'first-page': '271', 'article-title': 'Clinical characterization of 162 COVID-19 patients in Israel: ' 'preliminary report from a large tertiary center', 'volume': '22', 'author': 'Itelman', 'year': '2020', 'journal-title': 'Israel Med Assoc J'}, { 'key': '10.1016/j.mehy.2020.110142_b0025', 'doi-asserted-by': 'crossref', 'first-page': '1129', 'DOI': '10.1161/01.RES.86.11.1129', 'article-title': 'Folic acid reverts dysfunction of endothelial nitric oxide synthase', 'volume': '86', 'author': 'Stroes', 'year': '2000', 'journal-title': 'Circ Res'}, { 'issue': '1', 'key': '10.1016/j.mehy.2020.110142_b0030', 'doi-asserted-by': 'crossref', 'first-page': '61', 'DOI': '10.1093/nutrit/nuw053', 'article-title': 'Role of folic acid in nitric oxide bioavailability and vascular ' 'endothelial function', 'volume': '75', 'author': 'Stanhewicz', 'year': '2016', 'journal-title': 'Nutr Rev'}, { 'issue': '1', 'key': '10.1016/j.mehy.2020.110142_b0035', 'doi-asserted-by': 'crossref', 'first-page': '22', 'DOI': '10.1161/hc0102.101388', 'article-title': 'Folic acid improves endothelial function in coronary artery disease via ' 'mechanisms largely independent of homocysteine lowering', 'volume': '105', 'author': 'Doshi', 'year': '2002', 'journal-title': 'Circulation'}, { 'issue': '3', 'key': '10.1016/j.mehy.2020.110142_b0040', 'doi-asserted-by': 'crossref', 'first-page': '237', 'DOI': '10.1161/01.CIR.97.3.237', 'article-title': '5-methyltetrahydrofolate, the active form of folic acid, restores ' 'endothelial function in familial hypercholesterolemia', 'volume': '97', 'author': 'Verhaar', 'year': '1998', 'journal-title': 'Circulation'}, { 'issue': '1', 'key': '10.1016/j.mehy.2020.110142_b0045', 'doi-asserted-by': 'crossref', 'first-page': '242', 'DOI': '10.1542/peds.2005-2143', 'article-title': 'Folate and vitamin B6 rapidly normalize endothelial dysfunction in ' 'children with type 1 diabetes mellitus', 'volume': '118', 'author': 'MacKenzie', 'year': '2006', 'journal-title': 'Pediatrics'}, { 'key': '10.1016/j.mehy.2020.110142_b0050', 'doi-asserted-by': 'crossref', 'first-page': '1314', 'DOI': '10.1161/01.CIR.91.5.1314', 'article-title': 'Nitric oxide is responsible for flow-dependent dilatation of human ' 'peripheral conduit arteries in vivo', 'volume': '91', 'author': 'Joannides', 'year': '1995', 'journal-title': 'Circulation'}, { 'issue': '2', 'key': '10.1016/j.mehy.2020.110142_b0055', 'doi-asserted-by': 'crossref', 'first-page': '319', 'DOI': '10.1016/j.jpeds.2014.10.050', 'article-title': 'A NOS3 polymorphism determines endothelial response to folate in ' 'children with type 1 diabetes or obesity', 'volume': '166', 'author': 'Wiltshire', 'year': '2015', 'journal-title': 'J Pediatr.'}, { 'issue': '10', 'key': '10.1016/j.mehy.2020.110142_b0060', 'doi-asserted-by': 'crossref', 'first-page': '1119', 'DOI': '10.1161/hc3501.095358', 'article-title': 'Folic acid prevents nitroglycerin-induced nitric oxide synthase ' 'dysfunction and nitrate tolerance', 'volume': '104', 'author': 'Gori', 'year': '2001', 'journal-title': 'Circulation'}, { 'issue': '14', 'key': '10.1016/j.mehy.2020.110142_b0065', 'doi-asserted-by': 'crossref', 'first-page': '1076', 'DOI': '10.1089/ars.2015.6329', 'article-title': 'Folic acid promotes recycling of tetrahydrobiopterin and protects ' 'against hypoxia-induced pulmonary hypertension by recoupling ' 'endothelial nitric oxide synthase', 'volume': '23', 'author': 'Chalupsky', 'year': '2015', 'journal-title': 'Antioxid Redox Signal'}, { 'issue': '1', 'key': '10.1016/j.mehy.2020.110142_b0070', 'doi-asserted-by': 'crossref', 'first-page': 'e248', 'DOI': '10.1542/peds.2012-1945', 'article-title': 'Cobalamin C defect presenting with isolated pulmonary hypertension', 'volume': '132', 'author': 'Iodice', 'year': '2013', 'journal-title': 'Pediatrics'}, { 'issue': '12', 'key': '10.1016/j.mehy.2020.110142_b0075', 'doi-asserted-by': 'crossref', 'first-page': '1707', 'DOI': '10.1007/s00431-014-2330-6', 'article-title': 'Reversible pulmonary arterial hypertension in cobalamin-dependent ' 'cobalamin C disease due to a novel mutation in the MMACHC gene', 'volume': '173', 'author': 'Gündüz', 'year': '2014', 'journal-title': 'Eur J Pediatr'}, { 'issue': '7', 'key': '10.1016/j.mehy.2020.110142_b0080', 'doi-asserted-by': 'crossref', 'first-page': '825', 'DOI': '10.1016/S0954-6111(03)00038-6', 'article-title': 'Association between hyperhomocysteinemia and primary pulmonary ' 'hypertension', 'volume': '97', 'author': 'Arroliga', 'year': '2003', 'journal-title': 'Respir Med'}], 'container-title': 'Medical Hypotheses', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0306987720321952?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0306987720321952?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 1, 23]], 'date-time': '2021-01-23T15:34:06Z', 'timestamp': 1611416046000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0306987720321952'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 10]]}, 'references-count': 16, 'alternative-id': ['S0306987720321952'], 'URL': 'http://dx.doi.org/10.1016/j.mehy.2020.110142', 'relation': {}, 'ISSN': ['0306-9877'], 'subject': ['General Medicine'], 'container-title-short': 'Medical Hypotheses', 'published': {'date-parts': [[2020, 10]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'High dose folic acid is a potential treatment for pulmonary hypertension, ' 'including when associated with COVID-19 pneumonia', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Medical Hypotheses', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.mehy.2020.110142', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 Elsevier Ltd. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '110142'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit